adalimumab-adbm (Cyltezo) vs JNJ-78934804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02871635 · Phase 3 · completed
This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.
Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.
Reported efficacy
Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)
Result source: NCT02871635
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-adbm (Cyltezo) | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Trial running · NCT07577843 |
| Endoscopic response (induction) | —Not reported | —Trial running · NCT07577843 |
| Clinical remission (maintenance) | 68.6% vs 76.2%vs Humira EUNCT02871635 | —Trial running · NCT07577843 |
| Endoscopic response (maintenance) | —Not reported | —Trial running · NCT07577843 |
Clinical remission (induction)
- adalimumab-adbm (Cyltezo)
- —Not reported
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (induction)
- adalimumab-adbm (Cyltezo)
- —Not reported
- JNJ-78934804
- —Trial running · NCT07577843
Clinical remission (maintenance)
- adalimumab-adbm (Cyltezo)
- 68.6% vs 76.2%vs Humira EUNCT02871635
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (maintenance)
- adalimumab-adbm (Cyltezo)
- —Not reported
- JNJ-78934804
- —Trial running · NCT07577843
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-adbm (Cyltezo) |
|---|---|
| Dropout rate | 25%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Discontinued due to AEs | 5.6%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Serious AEs | —BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results8.3%BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 2.8%BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Most frequent reported AEs | arthralgia 8.3% respiratory tract infection 6.9% crohn's disease 5.6% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 1 more resultnasopharyngitis 6.9% weight increased 4.2% arthralgia 2.8% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-adbm (Cyltezo)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · JNJ-78934804's landscape